The Department of Veterans Affairs, James A. Haley VA Medical Center s (JAHVAMC) intent to solicit sole source to Pacific Edge Diagnostics USA Ltd., for specialized reference laboratory services for Cxbladder molecular diagnostic testing. 1.OBJECTIVE: 1.1 JAHVAMC requires Cxbladder testing for patients with suspected urothelial carcinoma, a history of urothelial carcinoma, or urinary tract abnormalities that cannot be definitively classified by routine morphologic evaluation alone. Cxbladder testing evaluates urinary messenger RNA (mRNA) biomarkers associated with urothelial carcinoma and provides clinically relevant molecular information to support diagnostic clarification, risk stratification, surveillance, and informed treatment decisions. JAHVAMC seeks a firm fixed-price, cost-per-test contract consisting of one 12-month base period and four 12-month option periods. The Contractor shall furnish Cxbladder Triage® and Cxbladder Monitor® testing, including all required test kits, collection and shipping materials, specimen transportation, laboratory analysis, result reporting, technical support, and secure electronic access to finalized test results. 2. SCOPE: 2.1 The Contractor shall furnish all labor, materials, equipment, supplies, shipping services, technical expertise, reporting capabilities, and administrative support necessary to perform Cxbladder Triage and Cxbladder Monitor testing for JAHVAMC, located in Tampa, Florida. Cxbladder Triage and Cxbladder Monitor testing support the clinical evaluation and management of patients who may be at risk for urothelial carcinoma. 2.2 Cxbladder Triage assists clinicians in identifying patients who may require further diagnostic evaluation for urothelial carcinoma. The test supports risk assessment and may help reduce unnecessary invasive diagnostic procedures in patients with a low likelihood of malignancy. 2.3 Cxbladder Monitor supports surveillance of patients with a history of urothelial carcinoma by identifying molecular signals associated with possible recurrent or progressive disease. The test assists clinicians in determining the appropriate level and timing of follow-up evaluation. Determination by the Government not to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. 2.4 Important information: The Government is not obligated to, nor will it pay for or reimburse any costs associated with responding to this Special Notice. This notice shall not be construed as a commitment by the Government to issue a solicitation or ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. The Government will in no way be bound to this information if any solicitation is issued. No sub-contracting opportunity is anticipated. The North American Classification System (NAICS) code for this acquisition is 621511 Medical Laboratories with a size standard of $36.5 Million. Any offeror capable of providing this service shall notify the Contracting Officer by email within seven (7) calendar days from the date of the publication of this special notice. *Responses must include written documentation from the OEM, Pacific Edge Diagnostics USA Ltd., showing your company is an authorized service provider. All information is to be submitted no later than 2:00 PM EST, on Tuesday, November 23, 2026, to: keila.president@va.gov.